general talk, page-19

$6.6million as of march.

this trial isnt expensive vs other biotechs at all.

Also these options expiring December this year is another 2.1million that should come in before December.

Would expect conversion after kick off off phase 3, and share pirce comfortably back at 30c etc.

So yes their may be a cap raise soon, but literally at our lowest point equal to start of 2021.....it would be attractive for an investor but shitty for dilution and not required right now. I would expect end of Q3 on the back of trial starts, but prior to trial results, read outs etc.?